Merck's Keytruda blazes a path in first-line cervical cancer, making good on drugmaker's push for earlier patients

Kyle Blankenship

In the years since I/O wonder drug Keytruda’s initial approval, Merck has struck an aggressive clinical trial program, which is now firmly focused on earlier …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Merck's Keytruda blazes a path in first-line cervical cancer, making good on drugmaker's push for earlier patients

Kyle Blankenship

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

US warns drugmakers against misrepresenting cost of imported products

Geoffrey Porges exits Schrödinger with CFO swap; A new board seat for AstraZeneca's Pascal Soriot

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Merck's Keytruda blazes a path in first-line cervical cancer, making good on drugmaker's push for earlier patients